TargetMol

BIIB021

Product Code:
 
TAR-T2286
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2286-5mg5mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2286-1mL1 mL * 10 mM (in DMSO)£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2286-10mg10mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2286-25mg25mg£157.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2286-50mg50mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2286-100mg100mg£282.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2286-200mg200mg£432.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2286-500mg500mg£666.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BIIB021 is an orally-available, fully synthetic inhibitor of HSP90(Ki=1.7 nM, EC50=38 nM).
CAS:
848695-25-0
Formula:
C14H15ClN6O
Molecular Weight:
318.77
Pathway:
Autophagy; Cytoskeletal Signaling; Metabolism
Purity:
0.9838
SMILES:
COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C
Target:
HSP; Autophagy

References

1. Lundgren K, et al. Mol Cancer Ther, 2009, 8(4), 921-929. 2. B?ll B, et al. Clin Cancer Res, 2009, 15(16), 5108-5116. 3. Yin X, et al. Int J Cancer, 2010, 126(5), 1216-1225. 4. Zhang H, et al. Int J Cancer, 2010, 126(5), 1226-1234.